open access

Vol 60, No 2 (2009)
Postgraduate education
Published online: 2009-03-27
Submitted: 2013-02-15
Get Citation

Critical points in strategies for the diagnosis and treatment of osteoporosis

Roman S. Lorenc, Waldemar Misiorowski, Elżbieta Karczmarewicz
Endokrynologia Polska 2009;60(2):124-133.

open access

Vol 60, No 2 (2009)
Postgraduate education
Published online: 2009-03-27
Submitted: 2013-02-15

Abstract

Current treatment decisions for osteoporosis depend on the fracture risk calculated based on the results of comprehensive diagnostic procedures [clinical risk factors (CRF), densitometry (BMD), morphometry, and bone turnover markers (BTM)]. Recently developed fracture risk assessment tool (FRAXTM) represents an important new achievement as a 10-year fracture risk calculation based on femoral neck densitometry and age combined with independent clinical fracture risk factors. FRAXTM presents several options: FRAXTM BMI (body mass index) is advocated as a helpful screening tool to identify the group of patients with high fracture risk, independently of access to densitometry and FRAXTM, utilizing hip densitometry. In both cases, the probability of major fractures or hip fractures are calculated during performed diagnostic evaluations. Operating FRAXTM algorithm does not include spinal bone mineral density, which is its main limitation. With the aim of improvement of anti-fracture efficacy of therapeutic management of osteoporosis, we have extended our discussion to three integral elements of existent strategy: 1) screening outlines, 2) principles of drug selection, and 3) treatment benefit evaluation.
Since osteoporosis is a chronic disease, long-term adherence to the treatment is important. The suitability of the drug, the patient’s preference, tolerability, and convenience should all be considered. Anti-catabolic drugs are most appropriate in patients with high bone turnover, while anabolic drugs demonstrate efficacy irrespective of bone turnover. BMD measurement is most widely used for long-term assessment of the efficacy of osteoporosis treatment. The measurements of bone turnover markers (BTMs) can be considered a useful shortterm (at 3 months) monitoring tool in selected patients. In both BTM and BMD, the least significant change (LSC) method should be used for interpretation of the results. Fractures are not a reliable clinical endpoint for evaluating the effectiveness of therapy in individual patients because of their stochastic nature. If fractures occur, however, the need for drug change and additional non-pharmacological treatment (fall prevention, balance training, muscle strengthening) should always be considered.

Abstract

Current treatment decisions for osteoporosis depend on the fracture risk calculated based on the results of comprehensive diagnostic procedures [clinical risk factors (CRF), densitometry (BMD), morphometry, and bone turnover markers (BTM)]. Recently developed fracture risk assessment tool (FRAXTM) represents an important new achievement as a 10-year fracture risk calculation based on femoral neck densitometry and age combined with independent clinical fracture risk factors. FRAXTM presents several options: FRAXTM BMI (body mass index) is advocated as a helpful screening tool to identify the group of patients with high fracture risk, independently of access to densitometry and FRAXTM, utilizing hip densitometry. In both cases, the probability of major fractures or hip fractures are calculated during performed diagnostic evaluations. Operating FRAXTM algorithm does not include spinal bone mineral density, which is its main limitation. With the aim of improvement of anti-fracture efficacy of therapeutic management of osteoporosis, we have extended our discussion to three integral elements of existent strategy: 1) screening outlines, 2) principles of drug selection, and 3) treatment benefit evaluation.
Since osteoporosis is a chronic disease, long-term adherence to the treatment is important. The suitability of the drug, the patient’s preference, tolerability, and convenience should all be considered. Anti-catabolic drugs are most appropriate in patients with high bone turnover, while anabolic drugs demonstrate efficacy irrespective of bone turnover. BMD measurement is most widely used for long-term assessment of the efficacy of osteoporosis treatment. The measurements of bone turnover markers (BTMs) can be considered a useful shortterm (at 3 months) monitoring tool in selected patients. In both BTM and BMD, the least significant change (LSC) method should be used for interpretation of the results. Fractures are not a reliable clinical endpoint for evaluating the effectiveness of therapy in individual patients because of their stochastic nature. If fractures occur, however, the need for drug change and additional non-pharmacological treatment (fall prevention, balance training, muscle strengthening) should always be considered.
Get Citation

Keywords

fractures; BMD; bone turnover markers; osteoporosis; FRAXTM; bisphosphonates; PTH

About this article
Title

Critical points in strategies for the diagnosis and treatment of osteoporosis

Journal

Endokrynologia Polska

Issue

Vol 60, No 2 (2009)

Pages

124-133

Published online

2009-03-27

Bibliographic record

Endokrynologia Polska 2009;60(2):124-133.

Keywords

fractures
BMD
bone turnover markers
osteoporosis
FRAXTM
bisphosphonates
PTH

Authors

Roman S. Lorenc
Waldemar Misiorowski
Elżbieta Karczmarewicz

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl